Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06189053 · ClinicalTrials.gov registry record

A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)

A clinical trial of Myocarditis, sponsored by ModernaTX.

Active
Registry status
1,500
Enrollment target
1
Study location

NCT06189053: Active study of Myocarditis, sponsored by ModernaTX.

NCT06189053 is a study of Myocarditis that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 1,500 participants, above the 88-participant average among 5 other Myocarditis trials with a reported enrollment target (1605% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06189053, a study of Myocarditis, is active but no longer recruiting, sponsored by ModernaTX.

ACTIVE NOT RECRUITING
Registry status
1,500 participants
Enrollment target
1
Study location

Study Summary

The main goal of this study is to characterize presentation, clinical course, and long-term outcomes of myocarditis temporally associated with administration of mRNA-1273 (SPIKEVAX) COVID-19 vaccine.

Primary Outcome

Adverse clinical outcomes may include myocardial infarction, heart failure, stroke, and cardiovascular hospitalization.

Conditions Studied

Study Locations (1)

Illinois

  • Veradigm - Chicago

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2022-04-30
Est. Completion 2028-10-31
ModernaTX

90 total trials

What the registry record for NCT06189053 still lists

NCT06189053 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 88-participant average among 5 other Myocarditis trials with a reported enrollment target (1605% higher).

The record links to 1 condition, with Myocarditis appearing as the primary indexed condition, and to 0 interventions.

NCT06189053 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT06189053 about?

NCT06189053 is a clinical study titled "A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)". The main goal of this study is to characterize presentation, clinical course, and long-term outcomes of myocarditis temporally associated with administration of mRNA-1273 (SPIKEVAX) COVID-19 vaccine.

What is the current status of trial NCT06189053?

This trial is currently active not recruiting. The enrollment target is 1,500 participants. The study started on 2022-04-30. Estimated completion is 2028-10-31.

What conditions does trial NCT06189053 study?

This clinical trial studies the following conditions: Myocarditis.

Who is sponsoring clinical trial NCT06189053?

This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06189053 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myocarditis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00178724 · 1,500 participants

    Spinal Cord Injury Registry - North American Clinical Trials Network

  • NCT00951366 · 1,500 participants

    Preterm Lung Patient Registry

  • NCT01050504 · 1,500 participants

    Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

  • NCT02071134 · 1,500 participants

    Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06189053, the US trial registry maintained by the National Library of Medicine. NCT06189053 (large enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.